Tris Pharma Inc., a commercial-stage biopharmaceutical company focused on attention deficit hyperactivity disorder (ADHD), pain, addiction and neurological disorders, has appointed Michael Magee as vice president, quality and compliance.   “Michael joins Tris Pharma at an incredibly exciting time in which we have an established portfolio of ADHD medications and a diverse pipeline of late-stage assets, and where his proven track record in the pharmaceutical industry will play a key role in furt...